[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603864":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaccination group",null,"Lung cancer patients receive 23-valent pneumonia vaccine",[13],"Biological: 23-valent pneumococcal vaccine",{"label":15,"type":10,"description":16,"interventionNames":10},"Unvaccinated group","Lung cancer patients have not received the 23-valent pneumococcal vaccine",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BIOLOGICAL","23-valent pneumococcal vaccine","Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine",[9],{"type":24,"investigatorFullName":25,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yalei Zhang","100603864","an-observational-study-on-the-impact-of-the-23-valent-pneumonia-vaccine-on-lung-cancer-patients-100603864",false,"NCT07142057","An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients","An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients","Inclusion Criteria:\n\n1. Male or female patients \\>=18 years of age;\n2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;\n3. Never received pneumococcal vaccine\n\nExclusion Criteria:\n\nPatients having other factors that preventing researchers from enrollment them.","ALL","18 Years",{"count":36,"type":37},500,"ESTIMATED","OBSERVATIONAL","To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.",[41],"LUNG CANCER","NOT_YET_RECRUITING","2025-08-19",{"date":45,"type":46},"2025-08-26","ACTUAL",{"date":48,"type":37},"2025-09-01",{"date":50,"type":37},"2030-09-01",{"name":5,"class":6}]